Compare INGR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGR | GRFS |
|---|---|---|
| Founded | 1906 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 4.9B |
| IPO Year | 1997 | 2008 |
| Metric | INGR | GRFS |
|---|---|---|
| Price | $97.86 | $7.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $119.50 | $10.87 |
| AVG Volume (30 Days) | ★ 606.0K | 434.4K |
| Earning Date | 11-05-2026 | 07-28-2022 |
| Dividend Yield | ★ 3.41% | 1.14% |
| EPS Growth | ★ 15.14 | N/A |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $7,219,000,000.00 | N/A |
| Revenue This Year | N/A | $2.15 |
| Revenue Next Year | $1.96 | $6.22 |
| P/E Ratio | $24.28 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $93.72 | $6.96 |
| 52 Week High | $123.49 | $9.90 |
| Indicator | INGR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 58.74 |
| Support Level | $94.04 | $7.61 |
| Resistance Level | $104.60 | $8.36 |
| Average True Range (ATR) | 1.75 | 0.15 |
| MACD | 0.46 | 0.04 |
| Stochastic Oscillator | 69.29 | 90.83 |
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.